NCT07176988 Deconstructing Voice Therapy: Towards Enhanced Communication Outcomes
| NCT ID | NCT07176988 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Emory University |
| Condition | Dysphonia |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2025-09-03 |
| Primary Completion | 2029-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2025-09-03 with a primary completion date of 2029-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This research study aims to evaluate the effect of treatment delivery method on voice outcomes over 12 months in people with a primary complaint of a voice problem, diagnosed with either non-phonotraumatic vocal hyperfunction, also known as primary muscle tension dysphonia (MTD) or phonotraumatic vocal hyperfunction, also known as benign vocal fold lesions (lesions). The secondary objectives are: * To evaluate acoustic correlates of clear speech and the relationship to vocal acoustic and patient-reported voice outcomes. * To determine the association between overall dysphonia outcomes and adoption of clear speech.
Eligibility Criteria
Inclusion Criteria: * Non-smoking * Diagnosis of either primary muscle tension dysphonia of the hyperadducted type or benign vocal fold lesions. * No neuro-laryngologic or age-related vocal fold changes (e.g., atrophy) * No history of voice therapy or voice surgery in the last year * No history of other serious chronic medical conditions that may affect voice (per patient report), Normal hearing (determined by pure tone audiometry), stimulable and appropriate for behavioral voice intervention as determined by a voice-specialized speech-language pathologist and laryngologist, * Willingness to attend all therapeutic interventions and follow-up sessions * Willingness to use a smartphone to record practice Exclusion Criteria: * History of voice therapy or voice surgery in the last year * Serious chronic medical condition that may affect voice (per patient report) * Abnormal hearing ability (despite appropriate amplification) * Other laryngeal disorders not attributed to primary MTD and benign vocal fold lesions, * Not stimulable or inappropriate for behavioral voice intervention as determined by a voice-specialized speech-language pathologist and laryngologist * Unwillingness to attend therapeutic intervention and follow-up sessions * Unwillingness to use a smartphone to record practice * Pregnant women * Prisoners * Cognitive impairment or impaired decision-making capacity
Contact & Investigator
Amanda Gillespie, PhD
PRINCIPAL INVESTIGATOR
Emory University
Frequently Asked Questions
Who can join the NCT07176988 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, up to 65 Years, studying Dysphonia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07176988 currently recruiting?
Yes, NCT07176988 is actively recruiting participants. Contact the research team at amanda.i.gillespie@emory.edu for enrollment information.
Where is the NCT07176988 trial being conducted?
This trial is being conducted at Atlanta, United States.
Who is sponsoring the NCT07176988 clinical trial?
NCT07176988 is sponsored by Emory University. The principal investigator is Amanda Gillespie, PhD at Emory University. The trial plans to enroll 120 participants.